Evidence map›Paper›PMID 42830652›Full record

SynthesisMicrobiologyOpen2026

Iran's Escherichia coli AMR Landscape (2010-2025): A One Health Systematic Review and Meta-Analysis.

Arezoo Dehghan, Mina Arabian, Zahra Tahmasebi, Aliasghar Fakhri-Demeshghieh, Neda Baseri, Ehsan Mostafavi, Farzad Badmasti, Faranak Abnaroodhelleh, Arash Seifi, Fahimeh Bagheri Amiri

Abstract readSystematic ReviewMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in MicrobiologyOpen, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Arezoo DehghanDepartment of Epidemiology and Biostatistics, WHO Collaborating Center for Vector-Borne Diseases, Research Centre for Emerging and Reemerging Infectious Diseases, Pasteur Institute of Iran, Tehran, Iran.ORCID https://orcid.org/0009-0002-1965-4402
Mina ArabianDepartment of Epidemiology and Biostatistics, WHO Collaborating Center for Vector-Borne Diseases, Research Centre for Emerging and Reemerging Infectious Diseases, Pasteur Institute of Iran, Tehran, Iran.
Zahra TahmasebiDepartment of Epidemiology and Biostatistics, WHO Collaborating Center for Vector-Borne Diseases, Research Centre for Emerging and Reemerging Infectious Diseases, Pasteur Institute of Iran, Tehran, Iran.ORCID https://orcid.org/0009-0001-9270-9652
Aliasghar Fakhri-DemeshghiehDepartment of Epidemiology and Biostatistics, WHO Collaborating Center for Vector-Borne Diseases, Research Centre for Emerging and Reemerging Infectious Diseases, Pasteur Institute of Iran, Tehran, Iran.ORCID https://orcid.org/0000-0003-1693-533X
Neda BaseriDepartment of Bacteriology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
Ehsan MostafaviDepartment of Epidemiology and Biostatistics, WHO Collaborating Center for Vector-Borne Diseases, Research Centre for Emerging and Reemerging Infectious Diseases, Pasteur Institute of Iran, Tehran, Iran.ORCID https://orcid.org/0000-0002-1997-517X
Farzad BadmastiDepartment of Bacteriology, Pasteur Institute of Iran, Tehran, Iran.ORCID https://orcid.org/0000-0003-3502-147X
Faranak AbnaroodhellehHead of the Control and Supervision Group on the Production of Medicines and Biological Materials of the Iran Veterinary Organization, Tehran, Iran.
Arash SeifiCenter for Communicable Diseases Control (CDC), Ministry of Health and Medical Education, Tehran, Iran.
Fahimeh Bagheri AmiriDepartment of Epidemiology and Biostatistics, WHO Collaborating Center for Vector-Borne Diseases, Research Centre for Emerging and Reemerging Infectious Diseases, Pasteur Institute of Iran, Tehran, Iran.ORCID https://orcid.org/0000-0003-2943-2846

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Escherichia coli (E. coli) has developed resistance to multiple antibiotic classes, complicating treatment in both human and veterinary medicine. This study assesses the prevalence of antimicrobial resistance and antimicrobial resistance genes in E. coli in Iran, within a One Health framework encompassing humans, animals, foods, and the environment. We systematically searched Scopus, Google Scholar, Magiran, PubMed, Scientific Information Database Library (SID), and Web of Science, using keywords related to AMR and Escherichia coli, restricting to English and Persian publications from 2010 to January 2025. The risk of bias was evaluated using the JBI checklist for prevalence studies. Pooled prevalence and 95% confidence intervals (CIs) were calculated for each antibiotic using random-effects models. A total of 368 studies were included in the meta-analysis. The highest resistance was observed in the Classes of Penicillins (71.7, 95% CI: 65.6-76.6) and the lowest for Fosfomycins (6.8, 95% CI: 5.2-8.5). Resistance to Ceftizoxime, Ertapenem, Streptomycin, Piperacillin-Tazobactam, and Colistin increased over time. Phenotypically, 47.2%, 20.2%, and 14.1% of E. coli isolates were identified as extended-spectrum β-lactamase-producing (ESBL), AmpC, and metallo-beta-lactamase (MBL) producing, respectively. Among ESBL-producing isolates, the prevalence of bla

Indexed as

Anti-Bacterial AgentsDrug Resistance, BacterialDrug Resistance, Multiple, BacterialEscherichia coliEscherichia coli InfectionsAnimalsbeta-LactamasesHumansIranMicrobial Sensitivity TestsOne HealthPrevalenceAnti-Bacterial Agentsbeta-Lactamasesantimicrobial resistanceEscherichia coliIranone health

Identifiers

PMID42830652
PMCPMC13635689

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.